| Identification | Back Directory | [Name]
Ampalex | [CAS]
154235-83-3 | [Synonyms]
CX 516
Ampalex
Ampalex, >=98%
AMpakine CX516
BDP-12(Ampalex)
AMpalex (CX-516)
CX516; BDP 12; AMPAKINE CX516
SPD-420, BDP-12, CX-516, AMpalex
1-(6-Quinoxalinylcarbonyl)piperidine
1-Piperidinyl-6-quinoxalinylMethanone
1-(QUINOXALIN-6-YLCARBONYL)PIPERIDINE
6-(piperidin-1-ylcarbonyl)quinoxaline
Piperidine, 1-(6-quinoxalinylcarbonyl)-
Piperidin-1-yl-quinoxalin-6-ylmethanone
Methanone, 1-piperidinyl-6-quinoxalinyl-
ABT-224,PIPERIDINE, 1-(6-QUINOXALINYLCARBONYL)-
Ampalex
1-(Quinoxalin-6-ylcarbonyl)piperidine | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C14H15N3O | [MDL Number]
MFCD00943201 | [MOL File]
154235-83-3.mol | [Molecular Weight]
241.29 |
| Chemical Properties | Back Directory | [Melting point ]
88-90°C | [Boiling point ]
433.1±25.0 °C(Predicted) | [density ]
1.236±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Chloroform, Methanol | [form ]
powder | [pka]
-0.14±0.30(Predicted) | [color ]
white to light brown | [Water Solubility ]
H2O: 5mg/mL, clear | [InChI]
1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 | [InChIKey]
ANDGGVOPIJEHOF-UHFFFAOYSA-N | [SMILES]
O=C(C1=CC2=NC=CN=C2C=C1)N3CCCCC3 |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [RTECS ]
TM2785170 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Chemical Properties]
Tan Solid | [Uses]
It is one of a series of AMPA modulators | [Definition]
ChEBI: CX-516 is a N-acylpiperidine. | [Biochem/physiol Actions]
CX516 is a positive allosteric modulator at AMPA receptor that inhibits the deactivation of AMPA receptors. CX-516 is a nootropic and ampakine agent. | [in vivo]
The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.)[1]. | Animal Model: | Male Lister Hooded rats (56-63 postnatal day)[1] | | Dosage: | 5, 10, 20, and 40 mg/kg | | Administration: | Subcutaneously | | Result: | Two doses (10 and 20 mg/kg) were highly significant in improving the extradimensional shift deficit induced by either treatment regimes.
Two doses (5 and 40 mg/kg) was ineffective at reversing the extradimensional impairment induced by the sub-chronic postnatal phencyclidine treatment regime. |
|
|
|